162 related articles for article (PubMed ID: 15612152)
1. Bevacizumab for advanced colorectal cancer.
Hadj Tahar A
Issues Emerg Health Technol; 2004 Dec; (63):1-4. PubMed ID: 15612152
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab: new drug. Metastatic colorectal cancer: good in theory, not in practice.
Prescrire Int; 2006 Jun; 15(83):94-7. PubMed ID: 16764097
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer.
Heinemann V; Hoff PM
Oncology; 2010; 79(1-2):118-28. PubMed ID: 21088438
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
[TBL] [Abstract][Full Text] [Related]
6. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer.
Cohen MH; Gootenberg J; Keegan P; Pazdur R
Oncologist; 2007 Mar; 12(3):356-61. PubMed ID: 17405901
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Hurwitz H; Fehrenbacher L; Novotny W; Cartwright T; Hainsworth J; Heim W; Berlin J; Baron A; Griffing S; Holmgren E; Ferrara N; Fyfe G; Rogers B; Ross R; Kabbinavar F
N Engl J Med; 2004 Jun; 350(23):2335-42. PubMed ID: 15175435
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk.
Kabbinavar F; Irl C; Zurlo A; Hurwitz H
Oncology; 2008; 75(3-4):215-23. PubMed ID: 18852492
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T; Lindley C
Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer.
Hurwitz H; Kabbinavar F
Oncology; 2005; 69 Suppl 3():17-24. PubMed ID: 16301832
[TBL] [Abstract][Full Text] [Related]
11. The role of bevacizumab as first-line therapy for colon cancer.
Marshall J
Semin Oncol; 2005 Dec; 32(6 Suppl 9):S43-7. PubMed ID: 16399431
[TBL] [Abstract][Full Text] [Related]
12. Adding a humanized antibody to vascular endothelial growth factor (Bevacizumab, Avastin) to chemotherapy improves survival in metastatic colorectal cancer.
Clin Colorectal Cancer; 2003 Aug; 3(2):85-8. PubMed ID: 12952562
[No Abstract] [Full Text] [Related]
13. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events.
Hurwitz H; Saini S
Semin Oncol; 2006 Oct; 33(5 Suppl 10):S26-34. PubMed ID: 17145522
[TBL] [Abstract][Full Text] [Related]
14. Current perspective: bevacizumab in colorectal cancer--a time for reappraisal?
Okines A; Cunningham D
Eur J Cancer; 2009 Sep; 45(14):2452-61. PubMed ID: 19643598
[TBL] [Abstract][Full Text] [Related]
15. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer.
Hurwitz H
Clin Colorectal Cancer; 2004 Oct; 4 Suppl 2():S62-8. PubMed ID: 15479481
[TBL] [Abstract][Full Text] [Related]
16. Targeting vascular endothelial growth factor in colorectal cancer.
Berlin JD
Oncology (Williston Park); 2002 Aug; 16(8 Suppl 7):13-5. PubMed ID: 12199627
[TBL] [Abstract][Full Text] [Related]
17. New treatments for colorectal cancer.
FDA Consum; 2004; 38(3):17. PubMed ID: 15218840
[No Abstract] [Full Text] [Related]
18. Managing patients treated with bevacizumab combination therapy.
Gordon MS; Cunningham D
Oncology; 2005; 69 Suppl 3():25-33. PubMed ID: 16301833
[TBL] [Abstract][Full Text] [Related]
19. Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer?
Goldstein DA; El-Rayes BF
Oncologist; 2015 Sep; 20(9):981-2. PubMed ID: 26265225
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab in the treatment of metastatic colorectal cancer.
Caprioni F; Fornarini G
Future Oncol; 2007 Apr; 3(2):141-8. PubMed ID: 17381413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]